The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN6581572     3-(4-methylsulfinylphenyl)-2- pyridin-4-yl...

Synonyms: Skf-105809, SKF 105809, AC1L2W3W, 122454-69-7
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Skf-105809

  • The anti-inflammatory activity of SK&F 105809 and its metabolite were evaluated in an antigen-specific murine model of delayed type hypersensitivity (DTH) response, where they were found to affect only the inflammatory and not the induction phase of this response [1].
  • SK&F 105809 treated rats which received 30 mg/kg had significantly less brain edema, as measured by both gravimetry and water content, at 4 h after trauma [2].
  • SK&F 105809, a dual inhibitor of 5-LO/CO, significantly reduced hyperalgesia [3].
  • The present study was designed to determine the effect of a novel drug, SK&F 105809, a dual inhibitor of 5-LO and CO on cerebral edema formation after head injury in rats [2].

High impact information on Skf-105809


Associations of Skf-105809 with other chemical compounds

  • Furthermore, in a murine model of endotoxin shock in which animals are injected with LPS in combination with D-galactosamine (D-gal), SK&F 105809 (10, 30, and 100 mg/kg p.o.), delivered 30 min prior to LPS/D-gal, caused a dramatic reduction in serum TNF (40-90%) and protected the animals from the lethal effects of this treatment [6].

Gene context of Skf-105809


Analytical, diagnostic and therapeutic context of Skf-105809


  1. Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses. Reddy, M.P., Webb, E.F., Cassatt, D., Maley, D., Lee, J.C., Griswold, D.E., Truneh, A. Int. J. Immunopharmacol. (1994) [Pubmed]
  2. The mixed lipoxygenase/cyclooxygenase inhibitor SK&F 105809 reduces cerebral edema after closed head injury in rat. Shohami, E., Glantz, L., Nates, J., Feuerstein, G. Journal of basic and clinical physiology and pharmacology. (1992) [Pubmed]
  3. Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Griswold, D.E., Marshall, P., Martin, L., Webb, E.F., Zabko-Potapovich, B. Agents Actions Suppl. (1991) [Pubmed]
  4. Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivo. Griswold, D.E., Marshall, P.J., Lee, J.C., Webb, E.F., Hillegass, L.M., Wartell, J., Newton, J., Hanna, N. Biochem. Pharmacol. (1991) [Pubmed]
  5. Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Marshall, P.J., Griswold, D.E., Breton, J., Webb, E.F., Hillegass, L.M., Sarau, H.M., Newton, J., Lee, J.C., Bender, P.E., Hanna, N. Biochem. Pharmacol. (1991) [Pubmed]
  6. Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock. Olivera, D.L., Esser, K.M., Lee, J.C., Greig, R.G., Badger, A.M. Circ. Shock (1992) [Pubmed]
  7. Pharmacological profile of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Hanna, N., Marshall, P.J., Newton, J., Schwartz, L., Kirsh, R., Dimartino, M.J., Adams, J., Bender, P., Griswold, D.E. Drugs under experimental and clinical research. (1990) [Pubmed]
WikiGenes - Universities